DNDN: Dendreon Surges Double Digits Following Prostate Drug News

DNDN stock is up over 15% Monday

   

DNDN: Dendreon Surges Double Digits Following Prostate Drug News

Dendreon (DNDN) saw its stock soar following the company’s announcement that it will start selling its prostate cancer vaccine in Europe.

DendronLogo DNDN: Dendreon Surges Double Digits Following Prostate Drug NewsThe drug Provenge received European marketing approval in September for use in advanced prostate cancer patients. The drug’s launch — along with the company’s impressive fourth-quarter results — saw DNDN stock rise over 15% Monday.

Provenge reprograms the body’s immune cells in order to attack advanced prostate cancer cells. The drug has not been as successful as many thought it might be, but it’s still proven effective enough to hit the European markets.

Dendreon’s reported fourth-quarter revenue of $74.8 million, exceeding analysts’ expectations of $73 million.


Article printed from InvestorPlace Media, http://investorplace.com/2014/03/dndn-dendreon/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.